In comparison to the broad S&P 500 index closing the year to 31 December 2024 up by over 24%, the fall by more than 3% in the NASDAQ Biotech Index (NBI) over the same period was a disaster. Specialist investors in biotech companies may have felt like hiding under a rock while generalist investors probably now feel that any equity investment other than biotech would be a better home for their money.
Stock Watch: Biotech Investors Bid Good Riddance To 2024
Almost Everything That Could Go Wrong Did For Some Biotechs
From gene therapies to small molecule drugs, investors seemed to have eschewed the risks of biotech company investment propositions in 2024 but last year’s disappointments provided good lessons going forward.
